Complex Mitochondrial Dysfunction Induced by TPP+-Gentisic Acid and Mitochondrial Translation Inhibition by
Sebastián Fuentes-Retamal1, Cristian Sandoval-Acuña2, Liliana Peredo-Silva3
1Clinical and Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Abstract:
The mitochondrion has emerged as a promising therapeutic target for novel cancer treatments because of its essential role in tumorigenesis and resistance to chemotherapy. Previously, we described a natural compound, 10-((2,5-dihydroxybenzoyl)oxy)decyl) triphenylphosphonium bromide (GA-TPP+C10), with a hydroquinone scaffold that selectively targets the mitochondria of breast cancer (BC) cells by binding to the triphenylphosphonium group as a chemical chaperone; however, the mechanism of action remains unclear. In this work, we showed that GA-TPP+C10 causes time-dependent complex inhibition of the mitochondrial bioenergetics of BC cells, characterized by (1) an initial phase of mitochondrial uptake with an uncoupling effect of oxidative phosphorylation, as previously reported, (2) inhibition of Complex I-dependent respiration, and (3) a late phase of mitochondrial accumulation with inhibition of α-ketoglutarate dehydrogenase complex (αKGDHC) activity. These events led to cell cycle arrest in the G1 phase and cell death at 24 and 48 h of exposure, and the cells were rescued by the addition of the cell-penetrating metabolic intermediates l-aspartic acid β-methyl ester (mAsp) and dimethyl α-ketoglutarate (dm-KG). In addition, this unexpected blocking of mitochondrial function triggered metabolic remodeling toward glycolysis, AMPK activation, increased expression of proliferator-activated receptor gamma coactivator 1-alpha (pgc1α) and electron transport chain (ETC) component-related genes encoded by mitochondrial DNA and downregulation of the uncoupling proteins ucp3 and ucp4, suggesting an AMPK-dependent prosurvival adaptive response in cancer cells. Consistent with this finding, we showed that inhibition of mitochondrial translation with doxycycline, a broad-spectrum antibiotic that inhibits the 28 S subunit of the mitochondrial ribosome, in the presence of GA-TPP+C10 significantly reduces the mt-CO1 and VDAC protein levels and the FCCP-stimulated maximal electron flux and promotes selective and synergistic cytotoxic effects on BC cells at 24 h of treatment. Based on our results, we propose that this combined strategy based on blockage of the adaptive response induced by mitochondrial bioenergetic inhibition may have therapeutic relevance in BC.
Insights
A novel compound, GA-TPP+C10, targets breast cancer cell mitochondria, inhibiting energy production and inducing cell death. Combining this with doxycycline enhances its therapeutic potential by blocking cancer cell adaptation.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- Mitochondria are crucial in cancer development and chemoresistance, making them a key therapeutic target.
- The compound GA-TPP+C10 selectively targets breast cancer cell mitochondria, but its mechanism was unclear.
Purpose of the Study:
- To elucidate the mechanism of action of GA-TPP+C10 in breast cancer cells.
- To investigate the potential of a combined therapeutic strategy involving GA-TPP+C10 and doxycycline.
Main Methods:
- Assessing mitochondrial bioenergetics, including oxidative phosphorylation and respiration.
- Analyzing cell cycle progression, cell death, and metabolic remodeling.
- Investigating the effects of GA-TPP+C10 combined with doxycycline on mitochondrial function and cell viability.
Main Results:
- GA-TPP+C10 inhibits mitochondrial respiration complexes and α-ketoglutarate dehydrogenase complex activity, leading to G1 cell cycle arrest and cell death.
- Cancer cells exhibited metabolic adaptation, including increased glycolysis and AMPK activation, as a survival response.
- Combined treatment with GA-TPP+C10 and doxycycline synergistically enhanced cytotoxicity by inhibiting mitochondrial translation and adaptive responses.
Conclusions:
- GA-TPP+C10 effectively disrupts mitochondrial bioenergetics in breast cancer cells.
- Blocking cancer cell adaptive responses to mitochondrial inhibition enhances therapeutic efficacy.
- The combined strategy shows promise for breast cancer treatment.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Drugs that Stabilize Microtubules


